Conflicting findings between the Mitra-Fr and the Coapt trials: Implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation
Fig 2
Scatterplot of strategies plotted on an incremental cost-effectiveness plane (a); cost-effectiveness acceptability curve (CEAC) (b), both based on the Coapt data. In the CE plane the ellipse represents the 95% CI for the 500 means-centred replicates.